Abstract
This article reviews recent molecular dynamics simulations of the Alzheimer’s amyloid-β protein, the primary component of the amyloid plaques found in the brain of Alzheimer’s patients. Different simulation techniques, and their application to the study of monomeric, oligomeric, and fibrillar species is discussed. This review highlights how simulations have acted as an invaluable complement to experiment, providing atomistically detailed structural information about monomer, oligomer, and fibrillar structures, as well as mechanistic insights into the aggregation process of amyloid-β protein in the absence and presence of toxicity and aggregation inhibitors.
Keywords: Protein aggregation, Alzheimer Amyloid-β peptide, replica exchange molecular dynamics simulations, coarsegrained simulations
Current Topics in Medicinal Chemistry
Title:Insights into Aβ Aggregation: A Molecular Dynamics Perspective
Volume: 12 Issue: 22
Author(s): Joan-Emma Shea and Brigita Urbanc
Affiliation:
Keywords: Protein aggregation, Alzheimer Amyloid-β peptide, replica exchange molecular dynamics simulations, coarsegrained simulations
Abstract: This article reviews recent molecular dynamics simulations of the Alzheimer’s amyloid-β protein, the primary component of the amyloid plaques found in the brain of Alzheimer’s patients. Different simulation techniques, and their application to the study of monomeric, oligomeric, and fibrillar species is discussed. This review highlights how simulations have acted as an invaluable complement to experiment, providing atomistically detailed structural information about monomer, oligomer, and fibrillar structures, as well as mechanistic insights into the aggregation process of amyloid-β protein in the absence and presence of toxicity and aggregation inhibitors.
Export Options
About this article
Cite this article as:
Shea Joan-Emma and Urbanc Brigita, Insights into Aβ Aggregation: A Molecular Dynamics Perspective, Current Topics in Medicinal Chemistry 2012; 12 (22) . https://dx.doi.org/10.2174/1568026611212220012
DOI https://dx.doi.org/10.2174/1568026611212220012 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Membrane Interactions of Oligomeric Alpha-Synuclein: Potential Role in Parkinsons Disease
Current Protein & Peptide Science Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Deep Learning: A Breakthrough in Medical Imaging
Current Medical Imaging Caspase-3 Short Hairpin RNAs: A Potential Therapeutic Agent in Neurodegeneration of Aluminum-Exposed Animal Model
Current Alzheimer Research A Review of the Carbapenems in Clinical Use and Clinical Trials
Recent Patents on Anti-Infective Drug Discovery Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology Editorial (Hot Topic: Therapeutic Targets in Neurodegenerative Diseases)
Current Enzyme Inhibition Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages
Current Alzheimer Research Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Conformation as the Therapeutic Target for Neurodegenerative Diseases
Current Alzheimer Research Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer’s Disease
Current Alzheimer Research mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Current Alzheimer Research